Today, the Arizona Board of Regents announced a comprehensive, university-led statewide effort to address critical workforce shortages among physicians, nurses and other health care professionals. Currently, it is estimated nearly 3 million Arizonans have limited access to primary care, and more than one in three Arizona hospitals face a critical staffing shortage.Continue reading
Category Archives: AZBio News
Patients will lose access to 40% of future medicines because of the IRA, new research finds.
New research released by Vital Transformation (VT) shows that the Inflation Reduction Act (IRA) will stifle the ability of companies to continue research and development across a broad range of therapeutic areas. The effects of the IRA will have a far more serious impact on the development of new medicines than has been reported, according to the research.Continue reading
CEI Offers Course on Creating Your Quality Management System (QMS)
Get an overview of quality systems and understand the what and why founders need to know.Continue reading
GT Medical Technologies Marks a Clinical Milestone: 200th Patient Enrolled in the Multicenter Observational Registry of GammaTile® Therapy
Registry Study of GammaTile Surgically Targeted Radiation Therapy (STaRT) in Intracranial Brain NeoplasmsContinue reading
KOL Conversation: The Impact of the IRA on Oncology Patient Care
Impact of the IRA on Oncology Patient Care features an interview with Dr. Barbara L. McAneny, MD, FASCO, MACP Former President for the American Medical Association and the New Mexico Medical Society (NMMS); and currently CEO, New Mexico Cancer Center.
With Dr. Steve Potts CEO, Anticipate Bioscience.
Impact of the IRA on Oncology Patient Care was recorded on the 26th of May 2023Continue reading
Anuncia Medical Inc. Announces Published Data with Promising Clinical Outcomes Using the ReFlow™ Ventricular System In-Line with Hydrocephalus Shunts
SCOTTSDALE, Ariz., May 23, 2023 /PRNewswire/ — Anuncia Medical Inc. (“Anuncia” or the “Company”), a company specializing in advancing innovations for implantable and external cerebrospinal fluid (CSF) management systems and neurocritical care, is pleased to announce that an article highlighting its FDA cleared and CE Marked ReFlow™ Ventricular System “Gen 1” with Hydrocephalus shunts in patients suffering from chronic shunt occlusions, has been published in Pediatric Neurosurgery. Two years prior to being implanted with the ReFlow™ System, 7 of the 9 patients represented in the publication experienced a combined total of 14 proximal shunt failures that required revision. In the 2-4 years following ReFlow™ implantation and use to maintain flow, only 1 proximal shunt failure occurred amongst the 9 patients. As revisions are typically associated with expensive hospital admissions for both the child and family, reducing the number of revisions needed is invaluable to those impacted.Continue reading
Atlanta Nonprofit, Purple Pansies, Donates $726,000 in Support of TGen Clinical Study
PHOENIX, ARIZONA — MAY 23, 2023 — A $726,000 donation from Atlanta-based charity Purple Pansies will support a TGen-led clinical trial designed to increase a patient’s unfolded protein response (UPR) to push the cancer cells to reach a state of programmed cell death. UPR is a cellular defense mechanism that, when triggered, sends signals to the cell’s nucleus to restore balance and ensure that proteins are folded properly, which is essential for normal cell function.Continue reading
Ivy Brain Tumor Center Builds On Innovative Clinical Trial Program by Appointing New Chief Medical Officer
Leading Neuro-Oncologist Yoshie Umemura, MD, Joins Barrow Neurological InstituteContinue reading
AZAdvances Talent Receives Grant to Support STEM Workforce Opportunities
Senator Sinema lauds efforts to further fund growing internship program for Arizona studentsContinue reading